COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety and clinical activity of tamoxifen and the COX
inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin,
cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+,
human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study
could improve long-term outcomes for a subpopulation of women with aggressive stage I-III
ER+/HER2- breast cancer.